ORMP

Oramed Pharmaceuticals Inc. - 10-Q Summary

Business Context and Reporting Period

Oramed Pharmaceuticals Inc. is a development-stage biotechnology company focused on the research and development of orally ingestible insulin capsules and other polypeptide delivery systems. This report covers the nine-month period ended May 31, 2010. The company has not yet generated any revenue from operations and relies on financing and government grants to fund its activities.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss Reduction: The net loss decreased by approximately $548,000 compared to the prior nine-month period. This improvement is primarily attributed to government grants received from the Office of the Chief Scientist (OCS) in Israel totaling $450,717, which were netted against R&D expenses. No such grants were received in the comparable 2009 period.
• R&D Expenses: Reported R&D expenses dropped significantly from $1.5 million to $833,498 due to the aforementioned OCS grants and a decrease in materials purchased.
• G&A Expenses: General and administrative expenses increased by approximately $102,000, driven by higher investor relations costs and increased stock-based compensation ($319,943 vs. $113,195 in the prior period).
• Liquidity: Cash and cash equivalents decreased by $582,360 during the period. Short-term investments were reduced by $500,000.

Outlook, Risks, and Management Commentary

• Going Concern: The filing explicitly states substantial doubt regarding the company's ability to continue as a going concern. With an accumulated deficit of nearly $12 million and negative operating cash flows, the company lacks sufficient resources to meet requirements for the next 12 months without additional financing.
• Capital Requirements: Management estimates a need for approximately $6.6 million to fund operations for the twelve months following June 1, 2010. This includes $5.58 million for R&D and $1.03 million for G&A.
• Financing Strategy: The company is actively evaluating financing alternatives, including public or private equity offerings and continued funding discussions with the OCS. There is no assurance that financing will be secured.
• Operational Progress:
  • Oral Insulin: Phase 2B studies in South Africa were completed with positive safety profiles. Toxicology trials are underway.
  • GLP-1 Analog: Pre-clinical trials showed promise; human clinical trials were approved in Israel.
  • Rectal Application: Development has been temporarily suspended to focus resources on oral insulin.
• Subsequent Events:
  • Establishment of a joint venture, Entera Bio Ltd., with Laser Detect Systems (now D.N.A Biomedical Solutions) to develop oral delivery for osteoporosis.
  • Signing of a Manufacturing Supply Agreement with Sanofi-Aventis for insulin supply for U.S. clinical trials.
• Internal Controls: Management identified material weaknesses in internal controls over financial reporting, which continued during this quarter.

Investor Verification Checklist

• Capital Sufficiency: Verify the status of ongoing fundraising efforts given the explicit "going concern" warning and the $6.6 million funding gap.
• Grant Dependency: Assess the sustainability of operations given the heavy reliance on OCS grants to offset R&D costs.
• Clinical Milestones: Monitor the results of the toxicology trials and the upcoming Phase 2 studies required for FDA IND application.
• Related Party Transactions: Review the terms of the joint venture with Entera Bio and the significant stock option grants to directors (Nadav and Miriam Kidron).
• Internal Controls: Evaluate the impact of the disclosed material weaknesses in financial reporting on the reliability of future financial data.